A review of the metabolic effects of sibutramine

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 457-466

  Filippatos, T D ^a   Kiortsis, D N ^a   Liberopoulos, E N ^b   Mikhailidis, D P ^b   Elisaf, M S ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adipocytokines; Cholesterol; High density lipoprotein cholesterol; Insulin; Lipids; Sibutramine; Type 2 diabetes; Uric acid; Weight loss

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; DIANE; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LEPTIN; LIPID; METFORMIN; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; RESISTIN; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TROGLITAZONE; URIC ACID;

CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES CONTROL; DIET; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATTY LIVER; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERANDROGENISM; INSULIN SENSITIVITY; LIPID METABOLISM; MEDLINE; META ANALYSIS; METABOLIC PARAMETERS; METABOLIC REGULATION; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; BLOOD GLUCOSE; CHOLESTEROL; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; OBESITY; WEIGHT LOSS;

EID: 16844372969     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X38132     Document Type: Review

References (97)

1. Flegal KM, Carroll MD, Ogden CK, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc 2002;288:1723-7
2. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr Rev 2004;62(7 Pt 2):S120-6
3. Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr Drug Targets 2004;5:637-46
4. Avenell A, Broom J, Brown DJ, et al. Systemic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182
5. Avenell A, Brown DJ, McGee MA, et al. What interventions should we add to weight reduction diets in adults with obesity? A systemic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004;17:293-316
6. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systemic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003;27:1437-46
7. Arterburn DE, Crane PK, Veestra DL. The efficacy and safety of sibutramine for weight loss: a systemic review. Arch Intern Med 2004;164:994-1003
8. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-8
9. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22(Suppl. 1):S18-28
10. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129-34
11. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78
12. Heal DJ, Frankland AT, Gosden J, et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology (Berl) 1992;107:303-9
13. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997;21 (Suppl. 1):S25-9
14. Ryan DH. Clinical use of sibutramine. Drugs Today (Barc) 2004;40:41-54
15. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002;26(Suppl. 4):S29-33
16. Chapelot D, Marmonier C, Thomas F, Hanotin C. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000;68:299-308
17. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6:1-11
18. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6
19. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999;23:1009-15
20. Leung WY, Neil Thomas G, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003;25:58-80
21. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998;18:231-6
22. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160:2185-91
23. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25
24. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87
25. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94:152-8
26. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-12
27. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-23
28. Ersoz HO, Ukinc K, Baykan M, et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 2004;28:378-83
29. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002;16:5-11
30. Berube-Parent S, Prud'homme D, St-Pierre S, Doucet E, Tremblay A. Obesity treatment with a progressive clinical tritherapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes Relat Metab Disord 2001;25:1144-53
31. Fanghanel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003;20:101-13
32. Guven A, Koksal N, Cetinkaya A, Sokmen G, Ozdemir R. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004;6:50-5
33. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363-9
34. Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother 2004;5:633-42
35. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002;26(Suppl. 4):S38-41
36. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Safety 2003;26:1027-48
37. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98
38. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. J Am Med Assoc 2001;286:1331-9
39. Hansen D, Astrup A, Toubro S, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes Relat Metab Disord 2001;25:496-501
40. van Baak MA, van Mil E, Astrup AV, et al. Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr 2003;78:209-14
41. Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. Int J Obes Relat Metab Disord 2005;29:208-16
42. Gazi I, Liberopoulos E, Mikhailidis DP, Elisaf M. Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc Dis Prevent 2004;1:243-53
43. Van Gaal LF, Wauters M, Peiffer F, De Leeuw I. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes Relat Metab Disord 1998;8(Suppl. 1):S38-40
44. Kamel EG, McNeill G, Van Wijk MC. Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 2000;24:607-13
45. Porter JA, Raebel MA, Conner DA, et al. The Long-Term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004;10:369-76
46. Berkowitz RJ, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. J Am Med Assoc 2003;289:1805-12
47. Mersebach H, Klose M, Svendsen OL, Astrup A, Feldt-Rasmussen U. Combined dietary and pharmacological weight management in obese hypopituitary patients. Obes Res 2004;12:1835-43
48. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004;58:582-7
49. Sari R, Balci MK, Cakir M, et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004;30:159-67
50. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55
51. Van Gaal LF, Peiffer FW The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001;25(Suppl 4):S24-8
52. Valsamakis G, Chetty RK, Kumar S. The management of obesity in type 2 diabetes mellitus. Curr Med Res Opin 2002;18(Suppl. 1):75-81
53. Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000;16:114-24
54. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003;5:338-44
55. McLaughlin T, Abbasi F, Lamendola C, Kim HS, Reaven GM. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism 2001;50:819-24
56. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004;164:1395-404
57. Redmon JB, Raatz SK, Reck KP, et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 2003;26:2505-11
58. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001;24:1957-60
59. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-31
60. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med 2002;19:119-24
61. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004;26:1427-35
62. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17:222-9
63. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;55:589-612
64. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002;26(Suppl. 4):S34-7
65. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
66. Sabuncu T, Ucar E, Birden F, Yasar O. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab 2004;17:103-7
67. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, SAT Study Group. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004;112:201-7
68. Sonnichsen AC, Richter WO, Schwandt P. Reduction of lipoprotein(a) by weight loss. Int J Obes 1990;14:487-94
69. Boman L, Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes Surg 1997;7:125-7
70. Muls E, Kempen K, Vansant G, Cobbaert C, Saris W. The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a). Int J Obes Relat Metab Disord 1993;17:711-6
71. Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis 2001;11:153-7
72. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142:489-97
73. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84
74. Rissanen AM. Weight loss profile with Reductil in obese patients with type 2 diabetes: a double blind, placebo-controlled study. Obes Res 1999;7:S93
75. Angulo P. Nonalcoholic fatty liver disease. New Engl J Med 2002;346:1221-31
76. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92
77. Zelber-Sagi S, Kessler A, Brozowsky E, et al. Randomized placebo-controlled trial of orlistat for the treatment of patients with nonalcoholic fatty liver disease (NAFLD). Hepatology 2004;40:237A [abstract]
78. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-8
79. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131-4
80. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
81. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 2002;15:697-701
82. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55
83. Gokcel A, Gumurdulu Y, Karakose H, Karademir BM, Anarat R. Effects of sibutramine in non-dieting obese women. J Endocrinol Invest 2002;25:101-5
84. Yip I, Go VL, Hershman JM, et al. Insulin-leptin-visceral fat relation during weight loss. Pancreas 2001;23:197-203
85. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4
86. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med 2004;351:2599-610
87. Kim DM, Yoon SJ, Ahn CW, et al. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004;66(Suppl 1):S139-44
88. Stecc JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 2000;102:1634-8
89. Murray R. Polycystic ovary syndrome, obesity and insulin resistance: the new female triad. Adv Nurse Pract 2004;12:22-35
90. Sabuncu T, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 2003;80:1199-204
91. Konukoglu D, Serin O, Ercan M, Turhan MS. Plasmahomocysteine levels in obese and non-obese subjects with or without hypertension; its relationship with oxidative stress and copper. Clin Biochem 2003;36:405-8
92. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004;109(23 Suppl 1):III 15-9
93. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002;28(6 Pt 1):437-45
94. EMEA 2002: http://www.emea.eu.int/pdfs/human/referral/451402en.pdf
95. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005; 7:47-55
96. Hauner H, Meier M, Jockel KH, Frey UH, Siffert W Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003;13:453-9
97. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]. J Am Med Assoc 2001;285:2486-97